HIGHLIGHTS
- who: Richard Greil from the IIIrd Medical Department Paracelsus Medical University, Salzburg Salzburg, Austria have published the article: Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study, in the Journal: (JOURNAL)
- what: The analysis shows that patients treated with ibrutinib versus chlorambucil prior to obinutuzumab infusion had significantly lower increases from baseline for all cytokines and chemokines, except MIP-1u03b2. There was no difference, however, in PFS between the two arms (88% versus 87% at 2 years), although it . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.